OncoMatch/Clinical Trials/NCT06970743
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Is NCT06970743 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including BGB-16673 and Bendamustine for chronic lymphocytic leukemia.
Treatment: BGB-16673 · Bendamustine · Rituximab · Methylprednisolone — The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab) in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to covalent Bruton tyrosine kinase inhibitor(s) (cBTKi).
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: Bruton tyrosine kinase inhibitor
Previously received treatment for CLL/SLL with a covalent BTKi
Cannot have received: autologous stem cell transplant
Exception: unless ≥ 3 months after transplant
Prior autologous stem cell transplant (unless ≥ 3 months after transplant)
Cannot have received: CAR-T cell therapy
Exception: unless ≥ 6 months after cell infusion
chimeric antigen receptor-T cell (unless ≥ 6 months after cell infusion)
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate kidney function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify